Core Viewpoint - Multiple North Exchange 50 index funds have recently announced the suspension of large subscriptions to control capital inflow and maintain market stability, reflecting the growing interest in core assets of the North Exchange [1][2][3] Group 1: Fund Actions - ICBC Credit Suisse Fund announced the suspension of large subscriptions for its North Exchange 50 index fund, limiting daily purchases to 50,000 yuan, with a fund size of 517 million yuan and a year-to-date return of 31.3% as of May 27 [1] - Dongfang Caijing North Exchange 50 index fund also suspended large subscriptions, with a limit of 200,000 yuan, having a fund size of 782 million yuan and a year-to-date return of 31.84% [1] - Other funds, such as the China Europe North Exchange 50 index fund, have also implemented subscription limits, with a year-to-date return of 29.96% and a fund size of 750 million yuan [1] Group 2: Market Performance - The North Exchange 50 index has shown a strong upward trend since 2025, with a year-to-date increase of 34.67% as of May 28, outperforming the entire market [2] - In May, the North Exchange 50 index continued to rise, with an overall increase of 3.54% [2] - The North Exchange focuses on supporting "specialized, refined, distinctive, and innovative" enterprises, which, despite being smaller in scale, have high technological barriers and significant growth potential [2][3] Group 3: Investment Value - The North Exchange's liquidity and attention have significantly increased due to policy support and ongoing registration system reforms, providing a direct financing platform for early-stage high-growth companies [3] - The "specialized, refined, distinctive, and innovative" stocks in the North Exchange are expected to benefit from policy support, industry demand, and technological breakthroughs, offering high long-term investment value [3] - The North Exchange 50 index is becoming a focal point for capital inflow, with trading activity in its constituent stocks increasing [3]

每经记者｜任飞 每经编辑｜叶峰 近期，A股市场缩量震荡，题材板块继续快速轮动，而北证50指数则持续走强，创出历史新高。 记者注意到，今年以来，生物医药、人工智能以及北交所等行业及主题基金的表现依然不俗，在年内的净值排行当中，居于前列的产品普遍有此类基金的身 影。 值得注意的是，基金公司也在调整部分产品的申赎政策，近期又有一些基金公告限购方案，如易方达北证50成分指数、东财北证50指数发起等多只基金近期 公告了相关内容。有分析指出，在关注热门行业投资机会的同时，仍需关注外部不确定性带来的风险，并控制加仓节奏。 北证50指数再创新高，基金公司调整限购措施 近期，A股市场板块轮动依然较快，尽管单日上涨家数高于下跌家数的情况多次出现，但个股的赚钱效应却不佳，各宽基指数呈现出震荡走势。然而，北证 50指数却在近期表现活跃。 5月21日，北证50指数低开高走，再次创出历史新高，截至收盘，报收1479.81点。从《每日经济新闻》记者同业内人士交流的情况来看，基于目前北交所个 股量化交易的程度较低，资金仍有继续博弈的可能，不过，这也使得北交所相关主题基金的净值又一次提升。 Wind统计显示，截至5月20日，年内基金的净值收益 ...

-20% 0% 20% 40% 60% 80% 100% 北证50 沪深300 -40% ⚫⚫⚫⚫⚫⚫ 国银河证券|CGS 北交所日报 图2：北证与 A 股各行业当日涨跌幅（算数平均/%/ 2025.05.14) ■北交所算数平均涨跌幅 ■Ａ股算数平均涨跌幅 35 30 25 20 15 10 5 ■ 0 -5 资料来源：iFinD，中国银河证券研究院 请务必阅读正文最后的中国银河证券股份有限公司免责声明。 2 图1:北证成交额与换手率情况(截至2025.05.14) ■成交金额（合计/亿元) =换手率（算数平均/%） 600 16.0 14.0 500 12.0 400 10.0 300 8.0 6.0 200 4.0 100 2.0 0 0.0 03-19 04-15 05-14 02-13 0518 02-26 03-03 03-06 03-11 03-14 03-24 03-27 04-01 04-07 04-10 04-18 04-28 05-06 05-09 01-23 02-05 02-10 04-23 01- 01 资料来源：iFinD，中国银河证券研究院 可证券|CGS 北交所日报 今日涨跌 ...

Group 1 - Public funds are preparing for the second half of the year, with a significant increase in attention towards dividend assets, which are viewed as stable components in investment portfolios [1][2] - The average returns of active equity funds have shown recovery, with ordinary stock funds and mixed equity funds returning 2.13% and 2.28% respectively year-to-date as of April 30, and a one-year return of 6.95% [1] - The price-performance ratio of dividend assets, such as the CSI Dividend Index, is at the 99th percentile of the past decade, indicating that these assets are currently among the most cost-effective options [2] Group 2 - Certain low-volatility sectors with high dividend yields, such as banking, ports, hydropower, and logistics, are expected to perform steadily due to stable earnings and favorable dividend sustainability [3] - The Hong Kong stock market shows a valuation advantage for high-dividend stocks, supported by a conducive market environment for their performance [3] - Regulatory policies enhancing dividend oversight, combined with a low-interest-rate environment, are likely to accelerate the entry of long-term capital into the market, maintaining the investment value of Hong Kong dividend stocks [3]

Core Viewpoint - The overall valuation level of the Beijing Stock Exchange is considered high, with a median P/E ratio of 50.34 and an average of 68.9, but some companies still show investment value based on their performance and valuation [1] Group 1: Continuous High-Performance Stocks - This group consists of companies that have maintained positive growth in non-recurring net profit for three consecutive years, with Q1 growth not based on a low base from the previous year [2] - Among these, Tongli Co. has the lowest valuation at 11.2 times, with a Q1 non-recurring net profit growth rate of 60.66%, driven by increased sales of high-value products in the new energy and unmanned sectors, as well as overseas market expansion [2] - Other companies in this group, such as Kaifa Technology and Deyuan Pharmaceutical, also show double-digit growth in revenue and net profit, with Kaifa's growth primarily due to increased overseas demand [2][3] Group 2: Companies with High Exposure to the U.S. Market - This group includes companies with a high proportion of sales to the U.S., facing uncertainty in Q2 performance due to tariff impacts, with Q1 growth possibly influenced by preemptive stocking by U.S. clients [4] - Litong Technology has the lowest valuation in this group at 18.98 times, benefiting from recovery in downstream demand in the traditional engineering machinery sector [5] - Other companies like Jianbang Technology and Bond Co. also have significant sales exposure to the U.S. automotive parts market, with varying degrees of performance influenced by last year's low base [4][5] Group 3: Companies with Low Last Year’s Performance Base & Others - This group features companies with low performance bases from the previous year, leading to impressive Q1 growth, as well as those with relatively low valuations but promising full-year outlooks [6] - Qingju Technology, with the lowest valuation, is focused on debt restructuring but has shown a decline in Q1 performance, despite having a substantial order backlog [6][7] - Kangnong Seed Industry, despite a decline in Q1 revenue and net profit, remains a strong contender in the seed industry with expectations for future growth [7]

-40% -20% 0% 20% 40% 60% 80% 100% 北证50 沪深300 ⚫⚫⚫⚫⚫⚫ 资料来源：iFinD，中国银河证券研究院 请务必阅读正文最后的中国银河证券股份有限公司免责声明。 2 10 图1:北证成交额与换手率情况(截至2025.05.08) ■成交金额（合计/亿元) ●换手率（算数平均/%） 600 16.0 14.0 500 12.0 400 10.0 300 8.0 6.0 200 4.0 100 2.0 0 0.0 03-11 03-14 04-15 02-10 8T 70 ET 70 02-26 03-03 03-06 03-19 03-24 03-27 04-07 04-10 04-18 04-23 04-28 05-06 01-02 01-15 02-05 02-21 04-01 01-23 01- 01 可证券|CGS 中国银河证券|CGS 北交所日报 资料来源：iFinD，中国银河证券研究院 图2：北证与 A 股各行业当日涨跌幅（算数平均/%/ 2025.05.08) ■北交所算数平均涨跌幅 ■Ａ股算数平均涨跌幅 12 10 8 6 4 2 0 -2 -4 北交所日 ...

⚫⚫⚫⚫⚫⚫ 请务必阅读正文最后的中国银河证券股份有限公司免责声明。 -40% -20% 0% 20% 40% 60% 80% 100% 北证50 沪深300 ■北交所算数平均涨跌幅 ■Ａ股算数平均涨跌幅 7 6 5 4 3 2 l 0 -1 -2 -3 资料来源：iFinD，中国银河证券研究院 ■成交金额（合计/亿元) •换手率（算数平均/%） 600 16.0 14.0 500 12.0 400 10.0 300 8.0 6.0 200 4.0 100 2.0 0 0.0 2 2017 23 20 32 - 322 03-23 Ox.O> Ox 02-05- 0:51 03:57:3 Ox 10 Ox 1,0 01-05 03-2-2 ","s 01:10 01:20 ing St 01-02 01-15 01:23 ar 2 o 25 O3, Ja fift 图1：北证成交额与换手率情况（截至 2025.04.30) 北交所日报 2 □国银河证券|CGS 图2：北证与 A 股各行业当日涨跌幅（算数平均/%/ 2025.04.30) 资料来源：iFinD，中国银河证券研究院 河证券|CGS 北交所日报 表 ...

The provided content does not include any quantitative models or factors, nor their construction, evaluation, or backtesting results. The documents primarily consist of market data, stock performance tables, and general disclaimers. There is no relevant information to summarize regarding quantitative models or factors.

小宋我去某个四线城市尽调项目，做了一天访谈，晚上急需"回回血"。打开大众点评，搜索"按摩"，找到一间会所，看评论还算正规，我就去了。 安排给我的是一位看起来 40 多岁的姐姐，简称"吴姐"。 我刚躺下，吴姐就开腔：先生你是做金融的吧？ 我惊讶：你怎么看出来的？ 因为你操着普通话，说明是来出差的。然后，你看着年龄不大，但是有些秃顶，还有黑眼圈。 我们当地有很多挺大的企业，叫什么 ...ipo 阶段企业。像你这行业的人，我经常接待，都差不多长你这个样子。 我心想，这个姐有内容，有意思。"你干这行多久啦？" 吴姐说： 18 岁我就入行喽，也算是见过这行业的大风大浪的。 嗷？啥风浪？ 我入行的时候，按摩业务已经不能随便上了，要去 X 局审批，简称"审核制"。 然后呢，那个时候，很乱的，你只要 X 局里有人，就能上。要是没人呢，就找个对缝的，帮你对接 X 局的人。 然后，你得给帮你忙的人，一些好处。 我：还可以这么搞？不怕被查到嘛？ 吴姐：我们都很守规矩的，大家嘴都很严。上面要是问，就咬死说，是我们会所软硬件达标，是凭实力上的。 我：有意思。后来呢？ 后来肯定逐渐正规啦，这种灰色操作没得搞啦。再后来，说要提高市场效率， ...

Core Viewpoint - The public fund industry achieved impressive performance in Q1 2025, driven by a structural market led by AI and robotics themes [1][2]. Group 1: Fund Performance - The fund performance leaderboard for Q1 2025 was dominated by robotics-themed funds, Beijing Stock Exchange funds, and Hong Kong stock funds [2]. - The top-performing fund, Penghua Carbon Neutral Theme A, managed by Yan Siqian, achieved a return of 60.26%, heavily investing in several robotics stocks [3][5]. - Other notable funds include Ping An Advanced Manufacturing Theme A and Yongying Advanced Manufacturing Smart Selection A, both exceeding 50% returns, also focusing on robotics [6]. Group 2: Robotics Theme Funds - Penghua Carbon Neutral Theme A's significant holdings included stocks like Beite Technology and Hechuan Technology, with Double Forest Co. seeing a year-to-date increase of 118.16% [3][6]. - Fund managers expressed optimism about the rapid production of humanoid robots and the investment opportunities in new materials and technologies [7]. - The focus on core components and AI perception in humanoid robots indicates a growing market potential, with significant room for technological advancement [7][8]. Group 3: Beijing Stock Exchange Funds - Beijing Stock Exchange funds also performed well, with notable returns from funds like CITIC Construction Investment and Huaxia, achieving returns of 38.98% and 37.45% respectively [9]. - These funds have successfully identified high-performing stocks within the Beijing Stock Exchange, such as Kelaite, which saw a remarkable increase of 136.01% [9]. Group 4: Hong Kong Stock Funds - Hong Kong stock funds regained attention, with funds like Huatai Hong Kong Advantage Selection and Zhongyin Hong Kong Medical achieving returns of 38.9% and 32.25% respectively [12]. - The performance of these funds was bolstered by significant gains in pharmaceutical stocks, with companies like Kelun Pharmaceutical and Rongchang Biological seeing increases of 78.08% and 64.58% [12]. - The manager of Huatai Hong Kong Advantage Selection highlighted the growing competitiveness of Chinese innovative drugs in the global market, projecting a significant increase in overseas licensing deals [12][13].